Oncternal Therapeutics Inc - ESG Rating & Company Profile powered by AI
This webpage contains a questions and answers table on Oncternal Therapeutics Inc. Alternative corporations in the scoring peer group for Oncternal Therapeutics Inc are shown. Complete ESG assessment of Oncternal Therapeutics Inc can be reached by signing in.
Oncternal Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.8; made up of an environmental score of 4.0, social score of 5.3 and governance score of 4.6.
4.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1082 | Respiratorius AB (publ) | 4.9 | High |
| 1082 | Shenzhen Chipscreen Biosciences Co Ltd | 4.9 | High |
| 1121 | Oncternal Therapeutics Inc | 4.8 | High |
| 1121 | Heat Biologics Inc | 4.8 | High |
| 1121 | Curis Inc | 4.8 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Oncternal Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Oncternal Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Oncternal Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Oncternal Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Oncternal Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Oncternal Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Oncternal Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Oncternal Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Oncternal Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Oncternal Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Oncternal Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Oncternal Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Oncternal Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Oncternal Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Oncternal Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Oncternal Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Oncternal Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Oncternal Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.